Constrictive Pericarditis vs. Restrictive Cardiomyopathy: A Patient's Guide to Two Conditions That Look Alike but Need Very Different Treatments

Two patients walk into clinic on the same day with similar stories. Both are short of breath. Both have leg swelling. Both have a normal-looking ejection fraction on echocardiogram (the ultrasound measure of how well the heart squeezes). Both have elevated neck veins on exam (a sign that pressures inside the heart are high). The first patient had cardiac surgery 25 years ago. The second has a paraprotein on a routine blood panel (a blood protein abnormality that sometimes points to amyloid disease). Their physical exams look almost identical. Their echoes look broadly similar. And yet the right diagnosis for each one points to a completely different treatment, with one curable by surgery and the other needing disease-specific medication.

This is the classic diagnostic challenge in cardiology, telling constrictive pericarditis apart from restrictive cardiomyopathy. The two diseases produce a nearly identical clinical picture because they end up with the same physiologic problem (the heart can’t fill properly). But the biology behind them is completely different. The treatment is completely different. The prognosis is completely different. Getting the diagnosis right is what determines whether the patient gets a major curative operation or the wrong major operation, the right disease-specific therapy or the wrong empiric heart failure regimen.

This guide walks through what each condition is, why they look so similar, how cardiologists tell them apart, what the treatments are, what to expect during the workup and after the diagnosis, and what daily life looks like with each one. The goal is to give you the framework to follow what’s happening, ask the right questions, and understand why the workup is more involved than a single test.

What Are Constrictive Pericarditis and Restrictive Cardiomyopathy?

Both conditions cause the heart to fill poorly during the relaxation phase between beats (diastole). The squeeze function may be normal. The problem is that blood can’t get into the heart efficiently, so pressures back up, fluid accumulates, and the patient feels short of breath, swollen, and tired. The difference is what’s causing the filling problem. In constrictive pericarditis, the fibrous sac around the heart has become rigid and won’t let the heart expand. In restrictive cardiomyopathy, the heart muscle itself is stiff and won’t relax.

How a Normal Heart Fills

Each heartbeat has two phases. Systole is the squeeze (the heart contracts and pumps blood out). Diastole is the relaxation (the heart fills with the next batch of blood). For the heart to fill properly during diastole, the muscle needs to be able to relax and stretch, the pericardium needs to be flexible enough to let the heart expand, and the filling pressures need to be at a normal level.

What Goes Wrong in Constrictive Pericarditis

The pericardium is a thin, fibrous sac that surrounds the heart. Normally it’s flexible and has a small amount of lubricating fluid inside. In constrictive pericarditis, the pericardium becomes thickened, scarred, sometimes calcified, and rigid. The heart inside is structurally fine. It just can’t expand because the pericardium won’t let it. Imagine trying to fill a balloon inside a metal box. The balloon is fine; the box is the problem.

What Goes Wrong in Restrictive Cardiomyopathy

The heart muscle itself has become stiff, usually because of something infiltrating the tissue. Common infiltrative substances include amyloid protein (in cardiac amyloidosis), granulomas (in sarcoidosis), iron (in hemochromatosis), fibrous tissue (in endomyocardial fibrosis), or eosinophils (in hypereosinophilic syndrome). The infiltrated muscle can’t relax and stretch the way normal muscle does. Even with a normal pericardium around it, the heart can’t fill.

Why Both Look Similar

Both produce the same downstream picture: high filling pressures, fluid backing up into the lungs and the systemic veins, leg swelling, belly fluid (ascites), and eventually low cardiac output despite a normal ejection fraction. The pathophysiology converges, even though the underlying biology diverges.

Why the Distinction Changes Everything

Constrictive pericarditis is potentially curable. A surgical procedure called pericardiectomy strips the diseased pericardium off the heart. The heart, freed from the rigid encasement, can fill normally again. Functional capacity often improves dramatically. The operation is major, but the upside, when the diagnosis is right, is substantial.

Restrictive cardiomyopathy has no equivalent surgical cure. Treatment is targeted at the underlying cause (specific medications for cardiac amyloidosis, immunosuppression for sarcoidosis, iron removal for hemochromatosis). Standard heart failure medications often don’t work well in restrictive cardiomyopathy and can cause symptoms to worsen.

Mistaking restrictive cardiomyopathy for constrictive pericarditis and proceeding to pericardiectomy is a serious problem. The patient gets a major operation that doesn’t help, and the underlying restrictive disease continues to progress. Mistaking constrictive pericarditis for restrictive cardiomyopathy means missing a curable disease and managing the patient with palliative diuretics for years instead of fixing the actual problem.

What Causes Constrictive Pericarditis?

The most common causes are old cardiac surgery (the pericardium scars down over years), prior chest radiation (especially for Hodgkin lymphoma or breast cancer), prior viral or autoimmune pericarditis that resolved but left scarring, and tuberculosis (still common worldwide). Less common causes include connective tissue diseases, post-heart-attack pericarditis, and chronic kidney disease.

Post-Cardiac Surgery

Anyone who has had open heart surgery (coronary artery bypass grafting, valve replacement, congenital repair) can develop constrictive pericarditis years or decades later. The pericardium gets inflamed at the time of surgery and slowly scars. Constrictive symptoms can show up 5 to 30 years after the original surgery. This is the most common cause in Western countries.

Post-Radiation

Chest radiation for Hodgkin lymphoma (especially the higher doses used in the 1970s and 1980s), breast cancer, and certain lung cancers can damage the pericardium. Constrictive pericarditis can develop 10 to 40 years after the radiation. Patients treated in their twenties for Hodgkin lymphoma can present in their fifties or sixties.

Idiopathic and Post-Viral

A meaningful fraction of constrictive pericarditis cases are idiopathic (no clear cause) or post-viral (the patient had a self-limited viral pericarditis episode years earlier and the inflammation scarred down over time). The patient may not remember the original episode at all.

Tuberculosis

In countries with high TB prevalence, TB pericarditis is a major cause of constrictive pericarditis. TB pericarditis can resolve with treatment but leaves behind extensive scarring that produces constriction in a fraction of patients. Anyone with TB exposure history and unexplained heart failure deserves consideration of TB-related constrictive pericarditis.

Less Common Causes

Connective tissue diseases (lupus, rheumatoid arthritis), purulent bacterial pericarditis, malignancy with pericardial involvement, post-heart-attack pericarditis, and uremic pericarditis from kidney failure.

What Causes Restrictive Cardiomyopathy?

The most common causes are cardiac amyloidosis (the biggest single cause in adults today), cardiac sarcoidosis, hemochromatosis (iron overload), endomyocardial fibrosis, hypereosinophilic syndrome, and rare inherited forms. The specific cause matters because the treatment depends entirely on what’s infiltrating the heart muscle.

Cardiac Amyloidosis

The single most important cause of restrictive cardiomyopathy in adults today, and the diagnosis we look for first because the treatments have improved dramatically. Two main types:

ATTR amyloidosis (transthyretin amyloidosis): the most common form. Wild-type ATTR (also called senile cardiac amyloidosis) is especially common in older men. Hereditary ATTR is caused by inherited mutations and tends to present earlier. Treatment with tafamidis or vutrisiran can slow or stabilize the disease.

AL amyloidosis (light chain amyloidosis): from a clonal plasma cell disorder. Often more aggressive than ATTR. Treatment with daratumumab-based regimens, sometimes with stem cell transplant, can substantially improve outcomes when caught early.

The screening workup for amyloid typically includes serum and urine protein electrophoresis with immunofixation, free light chain assay, and a bone scintigraphy scan (PYP or DPD scan) that can identify ATTR amyloid in the heart. When AL is suspected, a fat pad biopsy or bone marrow biopsy is often done.

Cardiac Sarcoidosis

A granulomatous disease that can involve the heart in 5 to 10 percent of patients with sarcoidosis. Can present with restrictive physiology, conduction abnormalities, or ventricular arrhythmias. Treatment is immunosuppression (steroids, methotrexate, sometimes biologics). For more on this, see our guide to cardiac sarcoidosis.

Hemochromatosis

Iron overload disease, usually genetic (HFE gene mutations) or from repeated transfusions. Iron deposits in the heart muscle and produces restrictive cardiomyopathy. Treatment is phlebotomy (regular blood removal to reduce iron stores) or iron chelation therapy.

Endomyocardial Fibrosis

A condition that produces dense fibrosis of the inner layer of the heart muscle. More common in equatorial regions. Can be associated with hypereosinophilic syndrome.

Hypereosinophilic Syndrome

A disorder of high circulating eosinophils that can deposit in the heart and produce restrictive cardiomyopathy with endocardial damage. Treatment focuses on reducing eosinophil counts with steroids, hydroxyurea, or imatinib in some cases.

Inherited Restrictive Cardiomyopathy

Rare genetic forms exist, often associated with mutations in sarcomeric proteins. Family history matters.

Rarer Causes

Glycogen storage diseases, mucopolysaccharidoses, post-chemotherapy (especially anthracycline-related), post-radiation cardiomyopathy.

What Are the Symptoms?

The symptoms overlap heavily. Both produce shortness of breath (especially on exertion), leg swelling, abdominal fullness or ascites (fluid in the belly), fatigue, and exercise intolerance. Some patients have palpitations or fainting if conduction problems develop. The pattern of symptoms doesn’t reliably distinguish constrictive pericarditis from restrictive cardiomyopathy on its own; the imaging and physiology testing do.

Shortness of Breath

Both conditions raise the pressure in the pulmonary veins (the veins draining from the lungs back to the heart). The high pressure pushes fluid into the lung tissue, producing shortness of breath, especially when lying flat or with exertion. Patients often describe needing to prop themselves up on pillows at night (orthopnea) or waking up at night gasping for breath (paroxysmal nocturnal dyspnea).

Leg Swelling and Belly Fluid

High pressure on the right side of the heart pushes fluid out into the body’s tissues. Leg swelling (edema) is common, often pitting (you can press a finger into the skin and leave an indent). Abdominal fullness from ascites (fluid in the belly cavity) is common in more advanced cases. Some patients describe their pants getting tighter or their waistband not fitting.

Fatigue and Exercise Intolerance

Reduced cardiac output makes everyday activities feel hard. Walking up a flight of stairs becomes a chore. Patients often report needing to slow down or rest during activities they used to handle easily.

Right-Sided Symptoms Dominate

Unlike most forms of left heart failure, both constrictive pericarditis and restrictive cardiomyopathy tend to present with prominent right-sided symptoms (leg swelling, abdominal fullness, neck vein distention) early in the course. The lung congestion symptoms may come later or may not dominate the picture.

Conduction System Symptoms

Restrictive cardiomyopathy, especially cardiac sarcoidosis and amyloid, can involve the heart’s electrical conduction system. Patients may have palpitations, slow heart rates, or fainting from heart block. New-onset AFib is also more common.

Specific Clues to Underlying Cause

For amyloid: carpal tunnel syndrome (often years before cardiac symptoms), unexplained peripheral neuropathy, easy bruising or bleeding, macroglossia (enlarged tongue), nephrotic-range proteinuria, family history.

For sarcoidosis: prior diagnosis of pulmonary or other organ sarcoidosis, unexplained skin lesions, unexplained ocular inflammation, lymph node enlargement, atrioventricular block.

For hemochromatosis: family history, diabetes, liver disease, gray or bronze skin discoloration, joint pain.

For tuberculosis: history of exposure, recent immigration from a high-prevalence country, immunosuppression, B symptoms (fever, night sweats, weight loss).

How Are These Conditions Diagnosed?

A careful echocardiogram is the first test. Features that suggest constrictive pericarditis include septal bounce, respiratory variation in mitral inflow velocities, and a thickened pericardium. Features that suggest restrictive cardiomyopathy include thickened heart walls (especially in amyloid), characteristic strain patterns, and abnormal tissue Doppler findings. Cardiac MRI helps confirm constrictive findings and characterize the heart muscle in restrictive cases. Cardiac catheterization with simultaneous left and right heart pressure tracings is often the definitive test. Blood work and sometimes a biopsy nail down the underlying cause of restrictive cardiomyopathy.

The Echocardiogram

The starting point for almost every patient. An echocardiogram is an ultrasound of the heart that shows the chambers, the wall thickness, the ejection fraction, the valves, and characteristic patterns of how the heart fills.

In constrictive pericarditis, the echocardiogram typically shows: a normal or near-normal ejection fraction; normal wall thickness; a thickened or bright pericardium in some cases; characteristic septal bounce (a quick motion of the wall between the ventricles in early diastole); marked respiratory variation in mitral inflow velocities (the blood flow into the left ventricle changes substantially with breathing); preserved or increased tissue Doppler velocity at the medial mitral annulus despite the heart failure picture (a finding called “annulus paradoxus”).

In restrictive cardiomyopathy, the echocardiogram typically shows: a normal or near-normal ejection fraction; thickened heart walls in amyloid (often with a “speckled” or “granular” texture); enlarged atria; characteristic strain patterns (apical sparing in amyloid); reduced tissue Doppler velocities at the mitral annulus (the heart muscle is too stiff to relax); minimal respiratory variation in mitral inflow.

Cardiac MRI

Cardiac MRI provides higher-resolution images and can confirm or refute the echo findings. In constrictive pericarditis, MRI shows the thickened pericardium and can demonstrate adherence between the pericardium and the heart with breathing. In restrictive cardiomyopathy, MRI can show characteristic late gadolinium enhancement patterns (diffuse subendocardial enhancement in amyloid, patchy mid-wall enhancement in sarcoidosis, T2 elevation in active sarcoidosis). For more on what to expect, see our guide to cardiac MRI.

Cardiac Catheterization with Simultaneous Pressures

When the echocardiogram and MRI don’t give a clear answer, simultaneous left and right heart catheterization is the definitive test. Pressure catheters are placed in both the left and right ventricles, and the pressures are recorded simultaneously during respiration. In constrictive pericarditis, characteristic patterns include equalization of left and right ventricular end-diastolic pressures, ventricular interdependence (the left and right ventricular pressures move in opposite directions during inspiration), and a “dip-and-plateau” or “square-root sign” in the diastolic pressure tracing. In restrictive cardiomyopathy, the left ventricular pressure is usually higher than the right, and the variation with breathing is much less pronounced.

Blood Tests for Amyloid

Suspected restrictive cardiomyopathy triggers screening for amyloidosis: serum and urine protein electrophoresis with immunofixation, free light chain assay, and often a bone scintigraphy scan (technetium pyrophosphate or DPD scan) that can identify ATTR amyloid in the heart with high specificity.

Genetic Testing

When hereditary ATTR amyloidosis or other inherited forms of restrictive cardiomyopathy are suspected, genetic testing identifies specific mutations and informs family screening.

Endomyocardial Biopsy

In some cases, especially when amyloid is suspected but non-invasive testing is inconclusive, a biopsy of the heart muscle is needed. The biopsy is done via a catheter through the femoral or jugular vein. Sample tissue is analyzed for amyloid (with Congo red staining and mass spectrometry to determine the type), granulomas (for sarcoidosis), iron (for hemochromatosis), or other infiltrative findings.

Extracardiac Biopsy

When AL amyloidosis is suspected, a fat pad biopsy (a sample of subcutaneous fat from the abdomen) is often done as a less invasive alternative to heart biopsy. Bone marrow biopsy may also be done to evaluate the underlying plasma cell disorder.

How Should I Prepare for the Workup?

Bring a careful history of every cardiac and chest event in your past: surgeries, radiation, infections, autoimmune conditions, family history of heart disease, family history of amyloid or sarcoidosis. Bring a list of current medications. Be ready for an echocardiogram, possibly a cardiac MRI, blood work for amyloid markers, and possibly cardiac catheterization or biopsy. Plan for the workup to take several weeks, with multiple tests scheduled over that time.

A Careful Personal History

Document every cardiac event, surgery, or chest exposure:

Heart attacks, even small ones. Cardiac surgeries (CABG, valve, congenital repair) with dates and details. Heart catheterizations or angiograms. Pacemaker or defibrillator placement.

Chest radiation: how many treatments, what year, what was treated.

Pericarditis or pleurisy episodes, even if they seemed minor.

Episodes of unexplained fevers, joint pain, or rashes (possible autoimmune cause).

Tuberculosis exposure or known TB infection.

Recent or recurrent skin infections, ocular inflammation, lymph node enlargement (possible sarcoidosis).

Family History

Anyone in the family with: heart failure of unclear cause, especially before age 70; amyloidosis of any kind; sarcoidosis; hemochromatosis; sudden death; transplant for heart failure; pacemaker for heart block at a young age.

Medications and Supplements

Bring a complete list. Some medications worsen the picture (some calcium channel blockers, some heart failure drugs in restrictive cardiomyopathy). Some supplements interact with the workup or treatments.

Symptom Diary

Keep a brief log of symptoms in the weeks before your visit: what time of day they’re worst, what makes them worse, what you weigh in the morning, how much you’ve changed your activity. This is more useful than you might think.

Tests to Expect

Echocardiogram: 45 to 60 minutes, no special prep, eat normally, can drive yourself.

Cardiac MRI: 60 to 90 minutes, fasting may or may not be required depending on protocol, no metal on body, claustrophobia premedication if needed.

Blood work: standard fasting protocols if a lipid panel is included; otherwise no special prep.

Cardiac catheterization: nothing to eat or drink after midnight, hold certain medications per team instructions, arrange a ride home.

Endomyocardial biopsy: similar to catheterization, often done at the same setting.

Setting Up the Workup

The workup often happens over several weeks: first the echo, then the MRI a week or two later, then blood work and possibly a bone scintigraphy scan, then sometimes the cath and biopsy. Plan your calendar to accommodate.

What’s the Treatment for Constrictive Pericarditis?

The definitive treatment is pericardiectomy, a major heart surgery that removes the diseased pericardium and frees the heart to fill normally. Recovery takes weeks to months but functional improvement is often substantial. For patients who aren’t surgical candidates or have less severe disease, diuretics manage fluid overload and an anti-inflammatory trial (colchicine plus a brief course of steroids) is sometimes used early in the course when active inflammation is present.

Pericardiectomy

The cornerstone of treatment. A cardiac surgeon opens the chest, dissects the diseased pericardium off the heart, and removes as much of it as can be safely freed. The operation is performed either on cardiopulmonary bypass (a heart-lung machine) or sometimes off-bypass, depending on the surgeon’s preference and the anatomy.

The surgery is major. Cardiopulmonary bypass, careful dissection of pericardium that may be adherent to the heart muscle (sometimes to the point of being inseparable), and the postoperative recovery from a sternotomy all carry real risk. Operative mortality is 5 to 10 percent in most series, higher in patients with very advanced disease or significant comorbidities. The right operator and the right center matter.

The upside, when the diagnosis is correct, is substantial. Many patients report dramatic improvement in functional capacity, with reduced or eliminated diuretic requirements and return to exercise tolerance they hadn’t had in years. The benefit is often most apparent 3 to 6 months postoperatively, after the surgical recovery is complete and the heart has had time to adapt to its newly freed condition.

Anti-Inflammatory Therapy

For patients with constrictive pericarditis caught early, when there’s evidence of ongoing inflammation, a course of colchicine plus a brief course of steroids can sometimes reverse the constrictive physiology before the pericardium becomes irreversibly scarred. Cardiac MRI with gadolinium enhancement can identify inflammation. The trial is typically several months long, with reassessment of physiology and imaging.

Diuretics

Diuretics (furosemide, torsemide, spironolactone) manage the fluid overload symptoms (leg swelling, ascites, shortness of breath). They don’t fix the underlying problem, but they help patients feel better and function better while the workup proceeds or while the patient prepares for surgery.

Treatment of Underlying Cause

For TB-related constrictive pericarditis, antitubercular therapy is essential. For inflammatory pericarditis with ongoing inflammation, immunosuppression may be useful. For radiation-related constrictive pericarditis, no specific therapy beyond surgery and supportive care.

When Surgery Isn’t an Option

Some patients are too sick for surgery or have anatomy that makes pericardiectomy unfeasible. For these patients, medical management with diuretics and careful monitoring is the only option. Outcomes are generally worse than for patients who undergo successful surgery.

What Should I Expect If I Need Pericardiectomy? A Day-by-Day Walkthrough

Pericardiectomy is a sternotomy operation (the breastbone is opened) that takes 3 to 6 hours, requires 5 to 10 days in the hospital with the first 1 to 2 in the ICU, and needs 2 to 3 months of carefully paced recovery at home. The functional improvement is usually most noticeable around the 3-month mark, after the chest wall has healed and the heart has adapted to its newly freed condition.

The Two Weeks Before Surgery

You’ll have a pre-operative visit with the surgeon and an anesthesia consultation. Expect labs, an updated EKG, a chest CT scan, and sometimes a repeat echocardiogram or cath. The team will ask about every medication and supplement you take. Blood thinners (warfarin, apixaban, rivaroxaban, clopidogrel) get held on a specific schedule. Some blood pressure medications get held the morning of surgery. The surgeon and the anesthesiologist will both review the plan with you. You’ll be told when to stop eating and drinking the night before.

If you smoke, the team will push hard to get you to stop at least 2 weeks beforehand. Nicotine narrows the small blood vessels that supply the healing sternum and increases the risk of wound problems. Even cutting back substantially helps.

Pack a small bag for the hospital: a phone charger with a long cord, a robe that opens in the front, slip-on shoes, lip balm, ear plugs, an eye mask, a book or downloaded shows, glasses if you wear them. Leave valuables at home.

Surgery Day

You arrive early in the morning, change into a gown, and meet the OR team. An IV goes in. You’ll be wheeled to a pre-op holding area. The anesthesiologist places monitors and starts sedation. Once you’re asleep in the operating room, a breathing tube goes in, lines are placed in your neck and arm, and a urinary catheter is placed.

The surgeon opens the chest through the breastbone and identifies the diseased pericardium. The pericardium is dissected off the heart, often with a heart-lung machine providing circulation while the heart is worked on. Removing pericardium that’s stuck tightly to the heart muscle is the most delicate part and is where centers with experience really matter. The chest is then closed, the breastbone is wired back together, and you’re moved to the ICU.

Hospital Day 1 to 2 (ICU)

You wake up in the ICU with the breathing tube still in, sedated. As the anesthesia wears off, the team weans you off the ventilator and the tube comes out, usually within 12 to 24 hours. You’ll be hooked up to a heart monitor, an arterial line, drainage tubes from the chest, and a urinary catheter. Pain is managed with a pump you control. The first day is uncomfortable, and the deep breaths and coughing the nurses ask for feel hard, but they prevent pneumonia and atelectasis (collapsed lung tissue).

Hospital Day 3 to 5 (Step-Down Unit)

The chest tubes come out as drainage slows. The urinary catheter comes out. You start sitting at the edge of the bed, then standing, then walking with assistance. Your heart rhythm is watched closely. New atrial fibrillation is common in the first few days after open heart surgery and is managed with rate or rhythm medications. You’ll see a physical therapist and start basic breathing exercises with an incentive spirometer (the plastic device you suck on to expand your lungs).

Hospital Day 6 to 10 (Discharge Planning)

Once you can walk safely, eat regular food, manage pain with oral medications, and have stable vital signs, you’ll be cleared to go home. Discharge planning includes prescriptions, follow-up appointments, restrictions, and warning signs to watch for.

The First Two Weeks Home

The chest wall is sore. You’ll have a 6 to 8 inch incision over the breastbone with steri-strips or surgical glue. Driving is not allowed for about 4 weeks (the steering wheel could hit the chest in a sudden stop). Lifting more than 10 pounds is not allowed for 6 to 8 weeks. Showers are fine after the incision has dried; tub baths or pools are not until your team clears you.

Sleep is hard. Most patients sleep in a recliner or propped up in bed for the first few weeks because lying flat hurts the chest wall. A small pillow held against the chest helps when you cough or sneeze.

Weeks 3 to 6

The chest pain settles. Walking distances increase. Most patients can do gentle housework but should not vacuum, push a lawnmower, or carry groceries. The breastbone is healing but is not fully solid until about 8 weeks. You’ll have a follow-up with the surgeon and a follow-up with cardiology in the first 4 to 6 weeks after discharge.

Weeks 6 to 12

Driving resumes. Light lifting resumes. Cardiac rehabilitation usually starts at 4 to 6 weeks if the team thinks you’re ready. The functional improvement from the surgery itself starts to be clearly noticeable around this point.

Month 3 to 6

Many patients describe a turning point at the 3-month mark. The diuretic dose often comes down or comes off entirely. Exercise tolerance keeps climbing. The patients who were profoundly limited before surgery describe this stage as the moment they understood the operation worked.

When to Call the Team or Go to the ER

Call the team for any new or worsening shortness of breath, leg swelling, weight gain of 3 pounds in a day, fever above 100.4, new redness or drainage from the incision, or new palpitations. Go to the ER for chest pain that feels new or different, severe shortness of breath, fainting, or any symptom that feels emergent.

What’s the Treatment for Restrictive Cardiomyopathy?

Treatment depends entirely on the underlying cause. Cardiac amyloidosis has specific therapies (tafamidis or vutrisiran for ATTR, daratumumab-based regimens for AL, sometimes stem cell transplant). Cardiac sarcoidosis is treated with immunosuppression. Hemochromatosis is treated with phlebotomy or iron chelation. Standard heart failure medications are often poorly tolerated and need careful adjustment. Heart transplantation is the only option for advanced disease in selected patients.

Cardiac Amyloidosis: ATTR

For wild-type or hereditary ATTR amyloidosis, tafamidis stabilizes the abnormal transthyretin protein and slows disease progression. It’s given as a once-daily pill. Vutrisiran is an RNA-interference drug given as an injection every 3 months that reduces TTR production. Both are well tolerated and have changed the outlook for these patients substantially. Patisiran is another RNA-based option.

These drugs work best when started early in the disease course. Patients with advanced cardiac amyloidosis still benefit, but the benefit is greater when the disease is caught while heart function is still reasonably preserved.

Cardiac Amyloidosis: AL

AL amyloidosis is treated by targeting the underlying plasma cell disorder. The standard first-line regimen is daratumumab plus cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD). Patients with adequate cardiac and overall function may also be candidates for autologous stem cell transplantation. The treatment is coordinated with a hematologist who specializes in plasma cell disorders.

Cardiac function in AL amyloidosis can improve substantially with treatment of the underlying disease, though the recovery is slower than the improvement in markers of the plasma cell disorder.

Cardiac Sarcoidosis

Treatment is immunosuppression, typically starting with prednisone and adding steroid-sparing agents (methotrexate, azathioprine, sometimes biologics like infliximab) for longer-term control. The duration of treatment is often years. Cardiac MRI helps assess disease activity and response to treatment. See our guide to cardiac sarcoidosis for the full picture.

For patients with conduction system involvement (heart block) or ventricular arrhythmias, a pacemaker or implantable cardioverter-defibrillator may be needed.

Hemochromatosis

Phlebotomy (regular blood removal to reduce iron stores) is the cornerstone for genetic hemochromatosis. Iron chelation (deferasirox, deferoxamine) is used when phlebotomy isn’t feasible, especially in transfusion-associated iron overload. Treatment is long-term, sometimes lifelong.

Endomyocardial Fibrosis

Treatment depends on the stage. Early disease may respond to anti-inflammatory therapy. Advanced disease may require surgical resection of the fibrosed inner layer. Heart transplantation for end-stage disease.

Hypereosinophilic Syndrome

Treatment focuses on reducing eosinophil counts: prednisone, hydroxyurea, and imatinib (especially in FIP1L1-PDGFRA-positive cases). Mepolizumab is an IL-5 inhibitor used in some cases.

Standard Heart Failure Medications

Many of the standard heart failure drugs (ACE inhibitors, ARBs, beta-blockers) are not well tolerated in restrictive cardiomyopathy because these patients depend on adequate preload and a relatively fast heart rate to maintain cardiac output. The team starts low and titrates carefully, watching for symptomatic hypotension and worsening symptoms.

Diuretics

Diuretics manage fluid overload symptoms. Patients with restrictive cardiomyopathy often need higher doses than typical heart failure patients to manage the symptoms, but they’re also at risk for over-diuresis with drops in blood pressure.

Heart Transplantation

For advanced restrictive cardiomyopathy that’s not amenable to disease-specific therapy, heart transplantation is the last option. Eligibility depends on age, comorbidities, and the underlying disease (amyloid patients need to be selected carefully because the underlying plasma cell or amyloidosis can recur).

What Should I Expect During the Amyloid Workup? A Step-by-Step Walkthrough

The amyloid workup is the most common diagnostic detour for a patient with possible restrictive cardiomyopathy. It usually involves three pieces: a blood screen for AL amyloidosis (SPEP, UPEP, immunofixation, free light chains), a bone scintigraphy (PYP or DPD) scan for ATTR amyloidosis, and either a fat pad biopsy or referral to a hematologist if AL is suspected. The full workup typically takes 3 to 6 weeks from first labs to final diagnosis.

Step 1: The Blood Screen for AL Amyloidosis

These three blood tests get ordered first because AL is the more aggressive form and missing it has consequences. The labs are a simple blood draw, no fasting required, results back in 5 to 7 days at most labs.

Serum protein electrophoresis (SPEP) and urine protein electrophoresis (UPEP) look for an abnormal spike of protein that signals a clonal plasma cell disorder. Immunofixation typing identifies what kind of abnormal protein it is. Serum free light chain assay measures kappa and lambda light chains and the ratio between them. An abnormal kappa-to-lambda ratio strongly suggests a plasma cell disorder.

If any of the three is abnormal, the next step is a referral to a hematologist, often within a week or two. The hematologist will usually arrange a bone marrow biopsy to confirm the diagnosis and grade the underlying plasma cell disorder.

If all three are clean, AL amyloidosis is unlikely and the workup shifts to ATTR.

Step 2: The PYP Bone Scintigraphy Scan

The PYP scan (technetium pyrophosphate scintigraphy) is the breakthrough test for ATTR cardiac amyloidosis. It detects ATTR amyloid in the heart with high specificity once AL has been ruled out.

The scan takes a half-day appointment. You arrive at nuclear medicine, get an IV, and receive an injection of technetium-99m pyrophosphate. You then wait about 1 hour while the tracer distributes. The scan itself takes about 30 minutes. You lie flat on a table while a gamma camera moves around you. There’s no contrast, no claustrophobic tube, no breath holds. Some people find the wait more annoying than the scan.

The results are graded on a 0 to 3 scale. A grade 2 or 3 scan with negative AL bloodwork is diagnostic for ATTR cardiac amyloidosis without needing a biopsy. A grade 1 or 0 scan with the right clinical picture argues against ATTR. Equivocal scans sometimes need additional confirmation.

Step 3: Fat Pad Biopsy (When Needed)

If AL is suspected but the bloodwork was equivocal, or if tissue confirmation is needed for any reason, a fat pad biopsy is often the next step. This is a minor outpatient procedure done in the dermatology or general surgery office.

The doctor numbs a small area of skin on the lower abdomen, makes a tiny incision, and removes a small sample of subcutaneous fat. The procedure takes about 15 minutes. You’ll have a small bandage for a few days. The fat sample is sent for Congo red staining, which is the classic stain that confirms amyloid, and for mass spectrometry to determine which type of amyloid is present.

Fat pad biopsy has a higher yield in AL amyloidosis than in ATTR amyloidosis. A negative fat pad biopsy in someone with high clinical suspicion for amyloid doesn’t completely rule it out.

Step 4: Bone Marrow Biopsy and Hematology Referral

If the SPEP/UPEP/free light chain screen is abnormal, or if AL is confirmed on tissue biopsy, you’ll meet with a hematologist who specializes in plasma cell disorders. The first visit usually includes a full history and physical, additional labs, and a bone marrow biopsy.

The bone marrow biopsy is done in the hematologist’s office or an outpatient procedure suite. Local anesthetic is injected over the back of the hip bone. A small sample of bone marrow is taken with a special needle. The procedure takes about 20 minutes. The pulling sensation when the sample is taken is the part most patients remember; the discomfort is usually brief. You’ll have soreness over the hip for a day or two.

The bone marrow sample is analyzed for plasma cell percentage, for the clonal protein, and for any other features of the underlying disease.

Step 5: Endomyocardial Biopsy (Selected Cases)

If the non-invasive workup is inconclusive but cardiac amyloid is still strongly suspected, an endomyocardial biopsy may be the next step. This is done by an interventional cardiologist in the cath lab.

A small catheter is threaded through a vein in the neck or groin and into the right ventricle of the heart. A few tiny samples of heart muscle are taken. The procedure takes about an hour. You’ll go home the same day in most cases. The tissue samples are analyzed the same way as the fat pad samples, with Congo red and mass spectrometry.

Endomyocardial biopsy has the highest sensitivity but the highest invasiveness. It’s typically reserved for cases where the diagnosis matters and the non-invasive testing didn’t settle it.

Step 6: Cardiology Plan-of-Care Visit

Once the type of amyloidosis is established, you’ll have a sit-down with cardiology to plan therapy. For ATTR, this usually means starting tafamidis or vutrisiran and arranging long-term cardiology follow-up with serial echocardiograms and biomarkers. For AL, this means tight coordination with hematology, with the cardiologist watching for cardiac improvement as the plasma cell disorder is treated.

How to Prepare Yourself for This Workup

Bring every medication bottle to the first visit. Bring a written timeline of when symptoms started and how they’ve changed. Bring your family history written down, including age at onset of any cardiac problems in relatives. Tell the team about carpal tunnel surgery, easy bruising, tongue enlargement, kidney problems, or unexplained neuropathy; all of these are amyloid clues.

Plan your calendar to accommodate multiple appointments. The labs are quick. The PYP scan is a half day. The fat pad biopsy is an hour. The bone marrow biopsy is half a day. The full sequence over 3 to 6 weeks is doable while working, with some flexibility.

What Should I Watch for After Diagnosis and Treatment?

Both conditions need ongoing follow-up. Monitor your weight daily and report sustained gains to your team. Watch for worsening shortness of breath, increasing leg swelling, abdominal fullness, or new palpitations. Take medications as prescribed; missing doses of disease-modifying therapy in amyloidosis or sarcoidosis can let the underlying disease progress. Show up for follow-up imaging and lab work to track response to therapy.

Daily Weight Monitoring

Get a scale, weigh yourself every morning before breakfast, write the weight down. Sustained weight gain of 3 pounds in a week or 5 pounds in a month often signals worsening fluid overload before the symptoms feel severe. Call the team for sustained weight gain so the diuretic can be adjusted before you end up in the emergency room.

Symptom Monitoring

Track shortness of breath, leg swelling, exercise tolerance, and any new symptoms. Track them in the same way each week so you can spot changes early.

Medication Adherence

Disease-modifying therapies (tafamidis, daratumumab regimens, prednisone for sarcoidosis, phlebotomy for hemochromatosis) need consistent adherence. Use a pillbox, reminders, or a smartphone app. Missing doses lets the underlying disease progress.

Follow-Up Imaging

Restrictive cardiomyopathy follow-up often includes serial echocardiograms (every 6 to 12 months), cardiac MRI (every 1 to 2 years), and disease-specific markers (NT-proBNP, troponin, cardiac biomarkers for amyloid response).

Constrictive pericarditis follow-up after pericardiectomy includes assessment of symptom improvement, repeat echocardiogram to confirm resolved physiology, and management of any postoperative complications.

When to Call the Team

Call within a day for: sustained weight gain, worsening shortness of breath, increasing leg swelling, new abdominal pain or fullness, new palpitations, lightheadedness with standing, or any new symptom that worries you.

When to Go to the ER

For: severe shortness of breath, especially at rest; chest pain that’s new or worsening; fainting; severe palpitations with hypotension; signs of stroke; severe acute abdominal pain; or any symptom that feels emergent.

Common Questions Patients Ask Me

Why is it so hard to tell these two conditions apart?

Because they produce nearly identical clinical pictures. Both cause shortness of breath, leg swelling, fatigue, normal ejection fraction on initial echocardiogram, and elevated filling pressures. The difference is in subtle imaging findings, in specific catheterization patterns, and in biomarkers. A thorough workup is necessary to make the call confidently.

Can a single test give me the answer?

Sometimes, but often no. A clear positive bone scintigraphy scan can diagnose ATTR amyloidosis. A clear thickened pericardium on MRI with characteristic features can confirm constrictive pericarditis. A clear biopsy can confirm amyloid type. But often the diagnosis requires synthesizing several tests, which is why the workup takes time.

What’s the success rate of pericardiectomy?

In experienced centers, operative mortality is 5 to 10 percent. Functional improvement is reported in 70 to 90 percent of survivors. The best outcomes are in patients caught earlier in the disease course, before the heart muscle has been damaged by chronic constriction.

How long does it take to recover from pericardiectomy?

Hospital stay is typically 5 to 10 days. Full recovery to baseline activity is usually 2 to 3 months. Functional improvement may continue for 6 months or more as the heart adapts to its new condition.

Are the new amyloid drugs really that good?

Yes, especially for ATTR amyloidosis. Tafamidis has been shown to reduce cardiovascular death and hospitalization in ATTR cardiomyopathy patients. Vutrisiran further reduces production of the amyloidogenic protein. For AL amyloidosis, daratumumab-based regimens have dramatically improved outcomes over older regimens.

Can my family members get amyloidosis or sarcoidosis from me?

Hereditary ATTR amyloidosis can be passed to children (autosomal dominant). Wild-type ATTR is not inherited but is age-related. AL amyloidosis is not directly inherited. Sarcoidosis has some genetic risk but isn’t strictly inherited.

Can I exercise?

Both conditions reduce exercise capacity, but most patients should still exercise within their tolerance. Cardiac rehabilitation can help. Avoid sudden intense exertion if you have known significant disease, especially with conduction abnormalities. See our guide to cardiac rehabilitation for more.

Will I need a defibrillator?

Some patients with cardiac sarcoidosis or restrictive cardiomyopathy with associated ventricular arrhythmias need an ICD. The decision is individualized based on the underlying disease and specific risk factors.

Should I be screened if I have a relative with one of these conditions?

Yes, for many of the inherited forms. Hereditary ATTR amyloidosis: genetic testing of first-degree relatives is recommended. Hemochromatosis: HFE genetic testing of first-degree relatives. Some inherited forms of restrictive cardiomyopathy: genetic testing depending on the mutation.

How long can someone live with restrictive cardiomyopathy?

It depends heavily on the underlying cause and how early it’s caught. Cardiac amyloidosis with current treatments often allows years to decades of relatively stable function when caught early. Sarcoidosis with appropriate immunosuppression can be well-controlled long-term. Other causes vary substantially.

What if the workup doesn’t give a clear diagnosis?

This happens. Sometimes the patient has mixed physiology (some pericardial restriction plus some myocardial restriction). Sometimes the diagnosis is made over time as more information emerges. Sometimes empiric treatment of the most likely cause is tried with reassessment. The structural heart team and the cardiomyopathy specialist can help work through ambiguous cases.

Will I need a heart transplant?

A small fraction of patients with advanced restrictive cardiomyopathy progress to needing transplant. Most patients are managed long-term with disease-specific therapy. Transplant eligibility depends on age, comorbidities, and underlying disease.

Reference Tables

Comparing the Two Conditions

Workup Sequence

Treatment by Underlying Cause

A Final Note From Me

Constrictive pericarditis and restrictive cardiomyopathy look alike but require very different care. Getting the diagnosis right is one of the most consequential decisions in adult cardiology. The patient who has constrictive pericarditis and gets correctly diagnosed and operated on can return to a normal life. The patient with restrictive cardiomyopathy who gets started on the right disease-specific therapy can have years of stable function. The patient whose diagnosis is missed or wrong faces a much harder course.

If you have symptoms of right-sided heart failure with a normal ejection fraction, especially if you have a history of cardiac surgery, chest radiation, or any of the conditions associated with restrictive cardiomyopathy, push for a thorough workup. An echocardiogram alone often isn’t enough. Cardiac MRI, amyloid screening, sometimes catheterization with simultaneous pressures, and sometimes biopsy are all part of getting the answer.

If you have an established diagnosis, the patients who do best are the ones who take their disease-specific therapy consistently, monitor their weight daily, recognize early signs of fluid overload, and stay engaged with their team. Most of the bad outcomes I see happen when patients miss doses, ignore early symptoms, or stop following up.

If you’ve been told you might need pericardiectomy, the right operator and center matter. Outcomes are substantially better in centers that do this operation often. Ask about volume and outcomes when deciding where to have the procedure.

If you have questions about this differential, the workup, or the treatment of a confirmed diagnosis, our office can help. To get in touch, visit our practice website. For complex cases requiring imaging and structural heart evaluation, we work with the cardiomyopathy and structural heart teams at San Diego Cardiovascular Associates.

References

1. Welch, Tonia D. “Constrictive Pericarditis: Diagnosis, Management and Clinical Outcomes.” Heart 104, no. 9 (2018): 725-731.

2. Maron, Barry J., Jeffrey A. Towbin, Gaetano Thiene, et al. “Contemporary Definitions and Classification of the Cardiomyopathies.” Circulation 113, no. 14 (2006): 1807-1816.

3. Adler, Yehuda, Philippe Charron, Massimo Imazio, et al. “2015 ESC Guidelines for the Diagnosis and Management of Pericardial Diseases.” European Heart Journal 36, no. 42 (2015): 2921-2964.

4. Maurer, Mathew S., Jeffrey H. Schwartz, Balarama Gundapaneni, et al. “Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.” New England Journal of Medicine 379, no. 11 (2018): 1007-1016.

5. Kittleson, Michelle M., Frederick L. Ruberg, Amrut V. Ambardekar, et al. “2023 ACC Expert Consensus Decision Pathway on Multidisciplinary Care for the Patient With Cardiac Amyloidosis.” Journal of the American College of Cardiology 81, no. 11 (2023): 1076-1126.

6. Birnie, David H., William H. Sauer, Frank Bogun, et al. “HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated with Cardiac Sarcoidosis.” Heart Rhythm 11, no. 7 (2014): 1305-1323.

7. Pereira, Naveen L., Martha Grogan, and Gerald W. Dec. “Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 1 of a 2-Part Series.” Journal of the American College of Cardiology 71, no. 10 (2018): 1130-1148.

8. Mookadam, Farouk, Sahar S. Jiamsripong, and Bijoy K. Khandheria. “Constrictive Pericarditis and Restrictive Cardiomyopathy: Distinguishing Echocardiographic and Hemodynamic Features.” European Journal of Echocardiography 11, no. 7 (2010): 555-562.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.